Clinical Trial Update: A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries [Phase 3]

View source ↗

Summary

Phase 3 study update on implementation strategies for cabotegravir plus rilpivirine long-acting injectables in HIV-1 treatment across European countries; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• CAB+RPV Long-acting injectables

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2023-05-19